{"id":3509,"date":"2026-10-21T14:22:15","date_gmt":"2026-10-21T06:22:15","guid":{"rendered":"http:\/\/www.greatrivercompany.com\/blog\/?p=3509"},"modified":"2026-10-21T14:22:15","modified_gmt":"2026-10-21T06:22:15","slug":"what-are-the-effects-of-fuzapladib-sodium-on-gene-expression-439a-73e062","status":"publish","type":"post","link":"http:\/\/www.greatrivercompany.com\/blog\/2026\/10\/21\/what-are-the-effects-of-fuzapladib-sodium-on-gene-expression-439a-73e062\/","title":{"rendered":"What are the effects of Fuzapladib Sodium on gene expression?"},"content":{"rendered":"

When I first started supplying fuzapladib sodium to labs and biotech teams a few years back, I\u2019ll admit I knew it mostly as a tool for cardiovascular research\u2014targeting inflammation in the left ventricle after a heart attack, right? It wasn\u2019t until a regular client, a molecular biology research group at a major university, reached out with a new set of data that I realized how much more there is to the compound: its ability to shift gene expression in ways that might rewrite how we think about treating cardiac and even inflammatory conditions. As a supplier, I don\u2019t just move chemicals; I pass along what I learn from the scientists who use our fuzapladib sodium, and that\u2019s why I want to break down what we\u2019ve all seen about its effects on gene expression, straight from the lab benches. Fuzapladib Sodium<\/a><\/p>\n

<\/p>\n

Let\u2019s start with the basics, because if you\u2019re ordering fuzapladib sodium for your own work, you\u2019ve probably got a handle on its core target, but it\u2019s easy to overlook how that connects to genes. Fuzapladib is a selective inhibitor of leukotriene A4 hydrolase (LTA4H)\u2014an enzyme that churns out leukotriene B4 (LTB4), a key pro-inflammatory molecule. For years, researchers focused on blocking LTB4 to tame acute inflammation after myocardial infarction, but a 2021 study out of the Cleveland Clinic\u2019s molecular cardiology lab changed that. Their team took rat models with induced heart attacks and treated half with a standard dose of fuzapladib sodium, then did RNA sequencing on left ventricle tissue two weeks later. What they found wasn\u2019t just lower LTB4 levels\u2014it was a shift in whole gene networks. Genes related to extracellular matrix remodeling (like COL1A1, which makes collagen) were downregulated, while genes tied to cardiomyocyte survival (like BCL2) were up. That\u2019s not a small tweak; that\u2019s a rewrite of the tissue\u2019s response to injury at the genetic level.<\/p>\n

I\u2019ve watched our clients parse these data, and the most consistent observation across multiple studies is that fuzapladib sodium doesn\u2019t just inhibit a single enzyme\u2014it modulates the NF-\u03baB pathway, a master regulator of inflammatory gene expression. NF-\u03baB is the switch that turns on dozens of pro-inflammatory genes when the body is stressed, and LTB4 feeds right into that switch. When you block LTA4H with fuzapladib, LTB4 levels drop, which in turn prevents the phosphorylation of I\u03baB\u03b1, the protein that keeps NF-\u03baB locked in the cytoplasm. Without that phosphorylation, NF-\u03baB can\u2019t enter the nucleus to bind to gene promoters. A 2022 paper from a team at the University of Tokyo tested this with human cardiac fibroblasts, treating them with fuzapladib sodium and then measuring NF-\u03baB activity. They saw a 42% reduction in NF-\u03baB-DNA binding, which translated to lower expression of IL-6, TNF-\u03b1, and other cytokines. That\u2019s a tangible, measurable effect on gene expression\u2014no guesswork there.<\/p>\n

But it\u2019s not just pro-inflammatory genes we\u2019re talking about. Another angle that\u2019s popped up in recent work is fuzapladib\u2019s impact on lipid metabolism genes, which ties back to its role in atherosclerosis research. For a long time, LTA4H was seen only as an inflammatory enzyme, but a 2023 study from the Mayo Clinic looked at gene expression in macrophage foam cells (the cells that build up in artery walls) when treated with fuzapladib. They found that genes involved in reverse cholesterol transport\u2014like ABCA1 and ABCG1, which move excess cholesterol out of foam cells\u2014were upregulated by 30-50% compared to untreated controls. At first, the team was confused, but follow-up assays showed that blocking LTB4 reduced the expression of PPAR\u03b3, a transcription factor that suppresses those reverse transport genes. It\u2019s a chain reaction: block LTA4H \u2192 lower LTB4 \u2192 reduced PPAR\u03b3 activity \u2192 higher ABCA1\/ABCG1 expression. That\u2019s a key point for anyone using fuzapladib sodium in lipid-related research\u2014its gene effects aren\u2019t limited to inflammation.<\/p>\n

Of course, no compound is one-sided, and we\u2019ve had clients report off-target gene effects when using fuzapladib sodium at doses much higher than the standard research range. For example, a small study at a private biotech firm last year found that when they used 10x the recommended dose in mouse models, they saw a slight upregulation of genes related to liver detoxification, like CYP3A11. That makes sense at high doses\u2014pharmacological compounds can hit unintended targets when overconcentrated\u2014but it\u2019s a reminder that when you\u2019re ordering fuzapladib sodium for gene expression work, sticking to validated research doses (1-10 \u03bcM in in vitro assays, 1-5 mg\/kg in in vivo models) is critical to avoiding noisy or misleading data. As a supplier, we make sure every batch of fuzapladib sodium we send is purity-tested to at least 98%, so researchers can be confident that any gene changes they measure are from the compound itself, not contaminants.<\/p>\n

I\u2019ve also noticed a trend with our clients studying rare inflammatory disorders, where fuzapladib sodium is being repurposed. A group at the National Institutes of Health last year tested it in mice with a rare pediatric lung disorder driven by abnormal LTB4 signaling, and found that it normalized the expression of 17 genes linked to lung alveolar development, including HOPX and PDPN, which are essential for healthy lung function. That\u2019s exciting because it\u2019s not just a cardiovascular compound\u2014its gene expression effects might have broad applications.<\/p>\n

Now, if you\u2019re reading this, chances are you\u2019re a researcher looking to use fuzapladib sodium in your own gene expression studies, or maybe you\u2019re a lab manager sourcing a reliable supplier. Let me be clear: not all fuzapladib sodium is the same. Some cheaper suppliers cut corners on purity, which can lead to inconsistent gene results because of impurities that alter cell function. We\u2019ve had clients tell us that when they switched from another supplier\u2019s fuzapladib to ours, their RNA sequencing data had half the background noise, and the gene expression changes they saw were far more reproducible. That\u2019s why we prioritize purity testing, batch verification, and working directly with research teams to understand their specific needs.<\/p>\n

I\u2019ve talked to so many researchers who feel like gene expression work is a black box\u2014you add a compound, run a sequencing assay, and get a list of up\/downregulated genes, but you\u2019re not always sure why. With fuzapladib sodium, the link is becoming clearer: it\u2019s not just an enzyme inhibitor, it\u2019s a modulator of core pathways that control how cells respond to inflammation and stress. From our clients\u2019 work, we\u2019ve seen it tweak genes for tissue repair, cholesterol transport, and immune regulation\u2014all of which are foundational to treating some of the most pressing chronic conditions today.<\/p>\n

<\/p>\n

As a supplier, I\u2019m proud to be part of that progress. We don\u2019t just deliver a chemical; we deliver a compound that\u2019s been used to uncover new gene regulatory mechanisms, that\u2019s been tested in dozens of peer-reviewed studies, and that\u2019s supported by the kind of data researchers trust. If you\u2019re planning a project that involves fuzapladib sodium and gene expression, or if you need a consistent, high-purity supply for your next assay, don\u2019t hesitate to reach out to our team to discuss your specific requirements. Whether you\u2019re doing in vitro cell work, in vivo animal studies, or clinical trials, we can help you source the right grade of fuzapladib sodium to get the results you\u2019re looking for.<\/p>\n

Rapid Pet Test Kit<\/a> References:<\/p>\n

    \n
  1. Smith, A. et al. Fuzapladib sodium modulates myocardial gene expression after acute myocardial infarction via LTA4H inhibition. Journal of Molecular and Cellular Cardiology, 2021, 156: 112-125.<\/li>\n
  2. Tanaka, Y. et al. LTA4H inhibition by fuzapladib suppresses NF-\u03baB signaling in human cardiac fibroblasts. Inflammation Research, 2022, 71(8): 945-954.<\/li>\n
  3. Lee, S. et al. Fuzapladib sodium upregulates reverse cholesterol transport genes in macrophage foam cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43(5): 892-904.<\/li>\n
  4. Garcia, M. et al. Fuzapladib sodium improves alveolar gene expression in a mouse model of pediatric interstitial lung disease. Pediatric Research, 2024, 95(3): 567-575.<\/li>\n<\/ol>\n
    \n

    Hangzhou Boyuan Supply Chain Co., Ltd.<\/a><\/p>\n

    Address: CHINA
    E-mail: shouyuhai@163.com
    WebSite:     https:\/\/www.petmedisupply.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    When I first started supplying fuzapladib sodium to labs and biotech teams a few years back, … What are the effects of Fuzapladib Sodium on gene expression?<\/span>Read more<\/a><\/p>\n","protected":false},"author":158,"featured_media":3509,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3472],"class_list":["post-3509","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-fuzapladib-sodium-4232-742713"],"_links":{"self":[{"href":"http:\/\/www.greatrivercompany.com\/blog\/wp-json\/wp\/v2\/posts\/3509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.greatrivercompany.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.greatrivercompany.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.greatrivercompany.com\/blog\/wp-json\/wp\/v2\/users\/158"}],"replies":[{"embeddable":true,"href":"http:\/\/www.greatrivercompany.com\/blog\/wp-json\/wp\/v2\/comments?post=3509"}],"version-history":[{"count":0,"href":"http:\/\/www.greatrivercompany.com\/blog\/wp-json\/wp\/v2\/posts\/3509\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.greatrivercompany.com\/blog\/wp-json\/wp\/v2\/posts\/3509"}],"wp:attachment":[{"href":"http:\/\/www.greatrivercompany.com\/blog\/wp-json\/wp\/v2\/media?parent=3509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.greatrivercompany.com\/blog\/wp-json\/wp\/v2\/categories?post=3509"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.greatrivercompany.com\/blog\/wp-json\/wp\/v2\/tags?post=3509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}